Scemblix® (asciminib)
for Leukemia

Scemblix (asciminib) is an oral kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, including newly diagnosed patients (accelerated approval), those previously treated, or patients with the resistant T315I mutation. It uniquely targets the ABL myristoyl pocket, providing an alternative when other treatments fail or cause side effects.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia